Zydus Cadila gets final USFDA nod for Deferasirox Tablets to treat iron overload syndrome
It is used to treat iron overload caused by blood transfusions in adults and children who are at least 2 years old.
Ahmedabad: Zydus Cadila has received final approval from the USFDA to market Deferasirox Tablets in the strengths of 90 mg, 180 mg and 360 mg.
Deferasirox binds to iron and removes it from the bloodstream. It is used to treat iron overload caused by blood transfusions in adults and children who are at least 2 years old. It is also used to treat chronic iron overload syndrome caused by a genetic blood disorder (non-transfusion dependent thalassemia) in adults and children who are at least 10 years old.
The drug will be manufactured at the group's manufacturing facility at SEZ, Ahmedabad.
The group now has 291 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila is a global pharmaceutical company headquartered in Ahmedabad, India. The company discovers, develops, manufactures, and markets a broad range of healthcare therapies.
The group has manufacturing sites and research facilities spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh and Sikkim in India and in the US and Brazil.
Read also: Zydus Cadila, Gilead ink licensing agreement to manufacture, market Remdesivir
